Pluvicto

lutetium (177Lu) vipivotide tetraxetan

Approval

ApplicationNDA 215833
Approval dateMar 23, 2022
Approval year2022
SponsorNovartis

FDA-approved use

To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Pluvicto: